Your browser doesn't support javascript.
loading
Heparin Does Not Regulate Circulating Human PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) in a General Population-Brief Report.
Xia, Vivian Q; Ong, Chui Mei; Zier, Lucas S; MacGregor, John S; Wu, Alan H B; Chorba, John S.
Affiliation
  • Xia VQ; Division of Cardiology, Zuckerberg San Francisco General Hospital, CA (V.Q.X., L.S.Z., J.S.M., J.S.C.).
  • Ong CM; Department of Medicine (V.Q.X., L.S.Z., J.S.M., J.S.C.), University of California, San Francisco.
  • Zier LS; Department of Laboratory Medicine (C.M.O., A.H.B.W.), University of California, San Francisco.
  • MacGregor JS; Clinical Chemistry Laboratory, Zuckerberg San Francisco General Hospital, CA (C.M.O., A.H.B.W.).
  • Wu AHB; Division of Cardiology, Zuckerberg San Francisco General Hospital, CA (V.Q.X., L.S.Z., J.S.M., J.S.C.).
  • Chorba JS; Department of Medicine (V.Q.X., L.S.Z., J.S.M., J.S.C.), University of California, San Francisco.
Arterioscler Thromb Vasc Biol ; 43(2): 352-358, 2023 02.
Article in En | MEDLINE | ID: mdl-36475702
ABSTRACT

BACKGROUND:

PCSK9 (proprotein convertase subtilisin-kexin type 9) chaperones the hepatic LDLR (low-density lipoprotein receptor) for lysosomal degradation, elevating serum LDL (low-density lipoprotein) cholesterol and promoting atherosclerotic heart disease. Though the major effect on the hepatic LDLR comes from secreted PCSK9, the details of PCSK9 reuptake into the hepatocyte remain unclear. In both tissue culture and animal models, HSPGs (heparan sulfate proteoglycans) on hepatocytes act as co-receptors to promote PCSK9 reuptake. We hypothesized that if this PCSK9HSPG interaction is important in humans, disrupting it with unfractionated heparin (UFH) would acutely displace PCSK9 from the liver and increase plasma PCSK9.

METHODS:

We obtained remnant plasma samples from 160 subjects undergoing cardiac catheterization before and after administration of intravenous UFH. PCSK9 levels were determined using a commercial enzyme-linked immunosorbent assay.

RESULTS:

Median plasma PCSK9 was 113 ng/mL prior to UFH and 119 ng/mL afterward. This difference was not significant (P=0.83 [95% CI, -6.23 to 6.31 ng/mL]). Equivalence testing provided 95% confidence that UFH would not raise plasma PCSK9 by > 4.7%. Among all subgroups, only subjects with the lowest baseline PCSK9 concentrations exhibited a response to UFH (8.8% increase, adj. P=0.044). A modest correlation was observed between baseline plasma PCSK9 and the change in plasma PCSK9 due to UFH (RS=-0.3634; P<0.0001).

CONCLUSIONS:

Administration of UFH does not result in a clinically meaningful effect on circulating PCSK9 among an unselected population of humans. The results cast doubt on the clinical utility of disrupting the PCSK9HSPG interaction as a general therapeutic strategy for PCSK9 inhibition. However, the observations suggest that in selected populations, disrupting the PCSK9HSPG interaction could still affect PCSK9 reuptake and offer a therapeutic benefit.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Heparin / Proprotein Convertase 9 Limits: Animals / Humans Language: En Journal: Arterioscler Thromb Vasc Biol Journal subject: ANGIOLOGIA Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Heparin / Proprotein Convertase 9 Limits: Animals / Humans Language: En Journal: Arterioscler Thromb Vasc Biol Journal subject: ANGIOLOGIA Year: 2023 Document type: Article